Suppr超能文献

COVID-19 的抗病毒治疗。

Antiviral treatment of COVID-19.

机构信息

Department of Infectious Disease and Clinical, Microbiology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkey

Department of Infectious Disease, Faculty of Medicine, Hacettepe University, Ankara, Turkey

出版信息

Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145.

Abstract

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.

摘要

目前,针对 COVID-19 没有任何特效的抗病毒治疗方法。尽管大多数 COVID-19 患者的病程较轻或中度,但高达 5%-10%的患者可能会出现严重、甚至危及生命的病程,因此急需有效的药物。优化的支持性治疗仍然是治疗的主要方法。目前已有 300 多项临床试验正在进行,在这些试验中,各种抗病毒和免疫调节剂都处于评估 COVID-19 的不同阶段,其中一些将在未来几个月内公布。尽管通过随机对照研究迫切需要找到针对 COVID-19 的有效抗病毒治疗方法,但某些药物仍在全球范围内使用,其依据是体外或推断证据或观察性研究。本综述将回顾在土耳其和世界各地最常使用的药物,包括氯喹、羟氯喹、洛匹那韦/利托那韦、法匹拉韦和瑞德西韦。硝唑尼特和伊维菌素也被包括在本综述中,因为它们最近被报道在体外对 SARS-CoV-2 具有活性,并且被批准用于治疗其他一些人类感染。

相似文献

1
Antiviral treatment of COVID-19.
Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145.
3
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
4
Treatment options for COVID-19: The reality and challenges.
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
5
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
6
Race to find COVID-19 treatments accelerates.
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
7
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
8
[Chloroquine as a possible treatment for COVID-19].
Ned Tijdschr Geneeskd. 2020 Mar 11;164:D4936.
9
In Vitro Data of Current Therapies for SARS-CoV-2.
Curr Med Chem. 2020;27(27):4542-4548. doi: 10.2174/0929867327666200513075430.
10
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.

引用本文的文献

1
Recent advances of nanotechnology in COVID 19: A critical review and future perspective.
OpenNano. 2023 Jan;9:100118. doi: 10.1016/j.onano.2022.100118. Epub 2022 Dec 14.
4
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
6
7
ACE2: the node connecting the lung cancer and COVID-19.
Am J Cancer Res. 2024 Apr 15;14(4):1466-1481. doi: 10.62347/XJVE4569. eCollection 2024.
8
A Mini-Review on the Common Antiviral Drug Targets of Coronavirus.
Microorganisms. 2024 Mar 17;12(3):600. doi: 10.3390/microorganisms12030600.

本文引用的文献

1
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
3
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. eCollection 2020 Apr.
4
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
5
Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390-3396. doi: 10.26355/eurrev_202003_20706.
6
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Pharmacotherapy. 2020 May;40(5):416-437. doi: 10.1002/phar.2398. Epub 2020 May 6.
7
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
8
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Antiviral Res. 2020 Jun;178:104786. doi: 10.1016/j.antiviral.2020.104786. Epub 2020 Apr 3.
9
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
10
Potential therapeutic agents against COVID-19: What we know so far.
J Chin Med Assoc. 2020 Jun;83(6):534-536. doi: 10.1097/JCMA.0000000000000318.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验